EVALUATION OF HEALTH CARE RESOURCE UTILIZATION AND COSTS AMONG BIO-EXPERIENCED CROHN'S DISEASE PATIENTS TREATED WITH BIOLOGICS WITH TWO YEARS OF FOLLOW-UP

被引：0
|
作者：
Cyhaniuk, A. [1 ]
Zhao, R. [2 ]
Ding, Z. [3 ]
Gupta, P. [1 ]
Kachroo, S. [2 ]
机构：
[1] STATinMED Res, Plano, TX USA
[2] Janssen Sci Affairs LLC, Horsham, PA USA
[3] Janssen Sci Affairs LLC, Furlong, PA USA
来源：
VALUE IN HEALTH | 2022年 / 25卷 / 07期
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
EE484
引用
收藏
页码：S429 / S429
页数：1
相关论文
共 50 条
  • [21] Adherence to infliximab maintenance therapy and health care utilization and costs by Crohn's disease patients
    Kane, Sunanda V.
    Chao, Jingdong
    Mulani, Parvez M.
    [J]. ADVANCES IN THERAPY, 2009, 26 (10) : 936 - 946
  • [22] BARIATRIC SURGERY - COSTS AND RESOURCES UTILIZATION IN TWO YEARS FOLLOW UP IN THE BRAZILIAN PRIVATE HEALTH CARE SYSTEM
    Junqueira Junior, S. M.
    Luque, A.
    Oliveira, F. M.
    Oliveira, D.
    Cabra, H. A.
    [J]. VALUE IN HEALTH, 2017, 20 (05) : A234 - A234
  • [23] Effects of Fistula on Healthcare Costs and Utilization for Patients with Crohn's Disease Treated in a Managed Care Environment
    Cohen, Russell D.
    Waters, Heidi C.
    Tong, Boxiong
    Rahman, Mirza I.
    [J]. INFLAMMATORY BOWEL DISEASES, 2008, 14 (12) : 1707 - 1714
  • [24] Persistence, Dose Titration, and Health Care Resource Utilization Among Crohn’s Disease Patients Treated With Ustekinumab: A Real-World Analysis in the United States
    Camilo Obando
    Zhijie Ding
    Erik Muser
    Neel Vaidya
    Wenqin Qiang
    Xiaoxi Sun
    Huiqi Wang
    Rajesh Mallampati
    Lin Xie
    [J]. Advances in Therapy, 2020, 37 : 2127 - 2143
  • [25] Persistence, Dose Titration, and Health Care Resource Utilization Among Crohn's Disease Patients Treated With Ustekinumab: A Real-World Analysis in the United States
    Obando, Camilo
    Ding, Zhijie
    Muser, Erik
    Vaidya, Neel
    Qiang, Wenqin
    Sun, Xiaoxi
    Wang, Huiqi
    Mallampati, Rajesh
    Xie, Lin
    [J]. ADVANCES IN THERAPY, 2020, 37 (05) : 2127 - 2143
  • [26] Persistence, Health Care Resource Utilization, and Costs Among OnabotulinumtoxinA-Treated Patients with Cervical Dystonia in the US
    Dashtipour, K.
    Charles, D.
    Sadeghi, M.
    Heath, M.
    Rava, A.
    Liu, J.
    Sun, H.
    Dong, Y.
    Lee, J.
    [J]. MOVEMENT DISORDERS, 2023, 38 : S345 - S346
  • [27] Persistence, Health Care Resource Utilization, and Costs Among OnabotulinumtoxinA-Treated Patients With Cervical Dystonia in the US
    Dashtipour, Khashayar
    Sadeghi, Marjan
    Heath, Maria
    Rava, Andrew
    Liu, Jinjie
    Sun, Haiyan
    Dong, Yanan
    Lee, Jae
    [J]. TOXICON, 2024, 237 : 21 - 21
  • [28] HEALTHCARE RESOURCE UTILIZATION AND COSTS AMONG PATIENTS WITH MODERATELY-TO-SEVERELY ACTIVE CROHN'S DISEASE TREATED WITH USTEKINUMAB: REAL-WORLD EVIDENCE
    Bessissow, T.
    Narula, N.
    Ma, C.
    In, T. S. H.
    Eberg, M.
    Pone, E.
    Jairath, V
    [J]. VALUE IN HEALTH, 2022, 25 (12) : S97 - S98
  • [29] A controlled trial of the impact of infliximab upon health care utilization costs, and charges in patients with Crohn's disease
    Harrison, JR
    Rubenstein, JH
    Leff, AR
    Cohen, RD
    [J]. GASTROENTEROLOGY, 2003, 124 (04) : A521 - A521
  • [30] Costs and health care resource utilization among chronic obstructive pulmonary disease patients with newly acquired pneumonia
    Lin, Junji
    Li, Yunfeng
    Tian, Haijun
    Goodman, Michael J.
    Gabriel, Susan
    Nazareth, Tara
    Turner, Stuart J.
    Arcona, Stephen
    Kahler, Kristijan H.
    [J]. CLINICOECONOMICS AND OUTCOMES RESEARCH, 2014, 6 : 349 - 356
12345